Till startsida
Till innehåll Läs mer om hur kakor används på gu.se

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

Artikel i vetenskaplig tidskrift
Författare G Curigliano
H J Burstein
E P Winer
M Gnant
P Dubsky
S Loibl
M Colleoni
M M Regan
M Piccart-Gebhart
H-J Senn
B Thürlimann
F André
J Baselga
J Bergh
H Bonnefoi
S Y Brucker
F Cardoso
L Carey
E Ciruelos
J Cuzick
C Denkert
A Di Leo
B Ejlertsen
P Francis
V Galimberti
J Garber
B Gulluoglu
P Goodwin
N Harbeck
D F Hayes
C-S Huang
J Huober
K Hussein
J Jassem
Z Jiang
Per Karlsson
M Morrow
R Orecchia
K C Osborne
O Pagani
A H Partridge
K Pritchard
J Ro
E J T Rutgers
F Sedlmayer
V Semiglazov
Z Shao
I Smith
M Toi
A Tutt
G Viale
T Watanabe
T J Whelan
B Xu
Publicerad i Annals of oncology : official journal of the European Society for Medical Oncology
Volym 28
Nummer/häfte 8
Sidor 1700-1712
ISSN 1569-8041
Publiceringsår 2017
Publicerad vid Institutionen för kliniska vetenskaper, sektionen för onkologi, radiofysik, radiologi och urologi, Avdelningen för onkologi
Sidor 1700-1712
Språk en
Länkar dx.doi.org/10.1093/annonc/mdx308
Ämneskategorier Cancer och onkologi


The 15th St. Gallen International Breast Cancer Conference 2017 in Vienna, Austria reviewed substantial new evidence on loco-regional and systemic therapies for early breast cancer. Treatments were assessed in light of their intensity, duration and side-effects, seeking where appropriate to escalate or de-escalate therapies based on likely benefits as predicted by tumor stage and tumor biology. The Panel favored several interventions that may reduce surgical morbidity, including acceptance of 2 mm margins for DCIS, the resection of residual cancer (but not baseline extent of cancer) in women undergoing neoadjuvant therapy, acceptance of sentinel node biopsy following neoadjuvant treatment of many patients, and the preference for neoadjuvant therapy in HER2 positive and triple-negative, stage II and III breast cancer. The Panel favored escalating radiation therapy with regional nodal irradiation in high-risk patients, while encouraging omission of boost in low-risk patients. The Panel endorsed gene expression signatures that permit avoidance of chemotherapy in many patients with ER positive breast cancer. For women with higher risk tumors, the Panel escalated recommendations for adjuvant endocrine treatment to include ovarian suppression in premenopausal women, and extended therapy for postmenopausal women. However, low-risk patients can avoid these treatments. Finally, the Panel recommended bisphosphonate use in postmenopausal women to prevent breast cancer recurrence. The Panel recognized that recommendations are not intended for all patients, but rather to address the clinical needs of the majority of common presentations. Individualization of adjuvant therapy means adjusting to the tumor characteristics, patient comorbidities and preferences, and managing constraints of treatment cost and access that may affect care in both the developed and developing world.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?